Full Year 2023 Investor Presentation
6
Investor presentation
Full year 2023
Diabetes value market leadership reached 33.8%
60%
Novo Nordisk global diabetes value market shares
-Diabetes
-GLP-1
-Insulin
54.9%
54.8%
52.7%
50.4%
50%
44.3%
43.8%
44.6%
43.9%
•
40%
33.8%
31.9%
•
30.1%
29.3%
30%
0%
2021
2022
2023
CER: Constant exchange rates; IO: International Operations; NAO: North America Operations
Note: Sales growth rates are at CER
Source: IQVIA MAT, Nov 2023 (Spot rate); Volume growth based on Moving Annual Total (MAT); Market values are based on the list prices
Diabetes value market leadership expansion
driven by the GLP-1 franchise
Diabetes care sales grew by 29% (CER) with global value
market share increase driven by market share gains in both
IO and NAO.
•
•
Global diabetes value market share increased by 1.9%-
points to 33.8%
Exceeded our strategic aspiration for 2025 by achieving a
global diabetes market value of more than 1/3
Novo Nordisk continues to be the global market leader in
the GLP-1 segment with a 54.8% value market share
Estimated global GLP-1 share of total diabetes
prescriptions is ~6%
Novo NordiskⓇView entire presentation